Synchrony Medical Receives Strategic Investment to Enhance Airway Clearance Solutions
Synchrony Medical, a specialized company focused on revolutionizing respiratory care technology, has announced a significant development in its mission. With a fresh infusion of funds amounting to $1 million from the New Jersey Innovation Evergreen Fund (NJIEF), the company, well-known for its FDA-cleared LibAirty™ airway clearance system, is set to expand its operations across the nation.
This recent investment mirrors an earlier funding effort led by Edge Medical Ventures, positioning Synchrony Medical to accelerate its U.S. commercialization efforts. This boost will facilitate further clinical research and product development while increasing patient access to the innovative LibAirty™ system through a variety of healthcare settings including respiratory clinics, hospitals, and homecare networks.
About LibAirty™: A Groundbreaking Respiratory Solution
LibAirty™ represents a significant advancement in airway clearance technology by being the first system of its kind cleared by the FDA. It employs guided breathing techniques synchronized with targeted chest compressions, aiming to provide patients a more effective and comfortable method to clear their lungs with a simple daily treatment available at home. Frequent airway clearance is critical for patients suffering from chronic conditions such as chronic obstructive pulmonary disease (COPD), bronchiectasis, and cystic fibrosis.
Clinical evidence supports that LibAirty™ not only enhances sputum clearance but also improves user comfort compared to traditional devices. Patients using this system can maintain better lung health, potentially reducing hospital visits and enhancing their overall quality of life.
Innovation and Vision for the Future
Anat Shani, CEO of Synchrony Medical, shared the company’s vision, stating, "Synchrony's goal is to transform the treatment of chronic lung disease within the home environment. With partnerships from entities like Edge Medical and NJIEF, we have strategically established our U.S. headquarters in New Jersey, a hub for health innovation. This new funding will enable us to rapidly scale our commercial activities and improve access to LibAirty™ throughout the country."
The Role of NJIEF and Edge Medical Ventures
NJIEF functions as a public-private partnership orchestrated under the New Jersey Economic Development Authority (NJEDA), aimed at boosting high-potential companies that are pioneering and commercializing innovative technologies within the state. The recent investment complements the earlier backing from Edge Medical Ventures, which specializes in developing impactful medical technologies that exhibit strong clinical validation and have considerable global market prospects.
Shai Policker, Managing Partner at Edge Medical Ventures, commented on Synchrony’s capabilities, stating, "Synchrony’s LibAirty system embodies robust clinical validation combined with practical usability, demonstrating success as a proof-of-concept for our co-investment model alongside NJEDA. We are witnessing tangible signs of commercial growth, which indicates that Synchrony is poised to dominate the airway clearance sector."
About Synchrony Medical
Headquartered in Jersey City, New Jersey, with additional operations in Or Yehuda, Israel, Synchrony Medical is a commercial-stage company that specializes in creating advanced respiratory care solutions. The LibAirty™ system has been developed in collaboration with esteemed pulmonologists at Sheba Medical Center, inspired by established airway clearance techniques. This innovative product redefines respiratory therapy, creating a manageable daily routine that empowers patients with chronic lung disease to perform their treatments independently, thus setting new standards in healthcare. Founded at the MEDX Xelerator venture studio, supported by the Israeli Innovation Authority, Synchrony Medical aims to improve the lives of those affected by respiratory issues.
Frequently Asked Questions
What is the purpose of the NJIEF investment?
The NJIEF investment aims to support Synchrony Medical in expanding the commercialization of the LibAirty™ airway clearance system throughout the U.S.
What are the main benefits of the LibAirty™ system?
The LibAirty™ system offers effective lung clearance through a guided breathing technique combined with chest compressions, improving patients' quality of life.
How does Synchrony Medical plan to utilize the new funding?
The funding will accelerate U.S. commercial operations, enhance clinical research, and expand patient access to the product across various healthcare settings.
Who are the key partners involved with Synchrony Medical?
Key partners include Edge Medical Ventures and the New Jersey Innovation Evergreen Fund, both of which provide significant support for growth and innovation.
What is the significance of the location for Synchrony Medical?
Being headquartered in New Jersey, a dynamic health innovation hub, allows Synchrony Medical to benefit from a supportive ecosystem that fosters technological advancement.
